APPROVED FOR ALL STAGES OF APC^1,2

ROBERTO:

LOCALLY ADVANCED DISEASE

MICHAEL:

INTERMEDIATE-RISK

GEORGE:

BIOCHEMICAL FAILURE

PATIENT HISTORY AND DIAGNOSIS

Diagnosed with PCa 2 years ago
PSA was 6 ng/mL
Status post: Ventral hernia repair/mesh; Crohn’s disease
DRE: Left side slightly firmer
Prostate weight: 80 grams
Biopsy: 2 of 12 positive cores; 2 cores chronic prostatitis
Gleason score: 6 (3+3)
Refused treatment

PERSONAL AND FAMILY HISTORY

Divorced chef
Father, 81 years of age, has a history of PCa, Gleason score 8 (4+4); successful curative attempt (radical prostatectomy and radiation therapy)
Older brother has a history of PCa, Gleason score 7 (3+4), treated with radical prostatectomy at 58 years; recurrence 3 years later and currently on long-term ADT

1 YEAR LATER

PSA was 8 ng/mL
Recommended repeat biopsy; patient refused

PRESENT VISIT (2 YEARS AFTER DIAGNOSIS)

PSA is 16 ng/mL
Testosterone level: 435 ng/dL
Stage T3a, N0, M0; fixed on left
Biopsy: Entire left side positive; 3 of 6 positive cores on right
Gleason score: 7 (3+4)

Hypothetical patient based on patient types studied in clinical trials. The pivotal CS21 study included men aged ≥18 years with histologically confirmed adenocarcinoma of the prostate (all stages), for whom endocrine treatment was indicated (except for neoadjuvant therapy).¹

Abbreviations: ADT = androgen deprivation therapy; APC = advanced prostate cancer; DRE = digital rectal exam; PCa = prostate cancer; PSA = prostate-specific antigen.

Monthly Matters

Help make the most of your patient's treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.

One-month depot is ideal for my patients. They love to come in, get checked, and see their nurse practitioner to ask questions and get updated data about their condition.

Actual physician quote

REFERENCE: 1. FIRMAGON^® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.

Indication

FIRMAGON^® (degarelix for injection) is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.

Important Safety Information

FIRMAGON is contraindicated in patients with a history of severe hypersensitivity to degarelix or to any of the product components.

Hypersensitivity reactions, including anaphylaxis, urticaria, and angioedema, have been reported post-marketing with FIRMAGON. In case of a serious hypersensitivity reaction, discontinue FIRMAGON immediately if the injection has not been completed, and manage as clinically indicated. Patients with a known history of severe hypersensitivity reactions to FIRMAGON should not be re-challenged with FIRMAGON.

FIRMAGON is contraindicated in women who are or may become pregnant. FIRMAGON can cause fetal harm and loss of pregnancy when administered to a pregnant woman.

Long-term androgen deprivation therapy (ADT) may prolong the QT interval. Physicians should consider whether the benefits of ADT outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking drugs known to prolong the QT interval (e.g., Class IA or Class III antiarrhythmic medications.)

Therapy with FIRMAGON results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after FIRMAGON may be affected. The therapeutic effect of FIRMAGON should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.

The most common adverse reactions (≥10%) during FIRMAGON therapy included injection site reactions (e.g., pain, erythema, swelling, induration or inflammation), pyrexia, hot flashes, weight loss or gain, fatigue, and increases in serum levels of transaminases and gamma-glutamyltransferase. The majority of adverse reactions were Grade 1 or 2; 1% or less were Grade 3/4. Injection site reactions were mostly transient, of mild to moderate intensity, occurred primarily with the starting dose, and led to few discontinuations (<1%).

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

APPROVED FOR ALL STAGES OF APC^1,2

MICHAEL, 61

INTERMEDIATE-RISK APC*

MICHAEL, 61

INTERMEDIATE-RISK APC*

PATIENT HISTORY AND DIAGNOSIS

PERSONAL AND FAMILY HISTORY

1 YEAR LATER

PRESENT VISIT (2 YEARS AFTER DIAGNOSIS)

Monthly Matters

Help make the most of your patient's treatment experience

APPROVED FOR ALL STAGES OF APC1,2

MICHAEL, 61

INTERMEDIATE-RISK APC*

MICHAEL, 61

INTERMEDIATE-RISK APC*

PATIENT HISTORY AND DIAGNOSIS

PERSONAL AND FAMILY HISTORY

1 YEAR LATER

PRESENT VISIT (2 YEARS AFTER DIAGNOSIS)

Monthly Matters

Help make the most of your patient's treatment experience

APPROVED FOR ALL STAGES OF APC^1,2